Robert Wilson

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.